Data updated: Nov 8, 2026
PIPRACIL (piperacillin sodium) · Pfizer
Infectious Disease
Approved 1981-12-29
3
Indications
--
Phase 3 Trials
1
Priority Reviews
44
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1981-12-29
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
PIPRACIL Approval History
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
202 FDA actions from 1981 to 2008 · 1 indication expansions
Dec 2002 SUPPL Priority
Mfg
Oct 2002 SUPPL
Mfg
Oct 2002 SUPPL
Mfg
Oct 2002 SUPPL
Mfg
Oct 2002 SUPPL Priority
Mfg
Mar 2002 SUPPL
Mfg
Feb 2002 SUPPL Priority
Mfg
Feb 2002 SUPPL
Label
Oct 2001 SUPPL
Mfg
Aug 2001 SUPPL Priority
Mfg
Dec 2000 SUPPL
Mfg
Nov 2000 SUPPL Priority
Mfg
Mar 1999 SUPPL Priority
Mfg
Feb 1999 SUPPL
Mfg
Jul 1998 SUPPL
Mfg
Jul 1998 SUPPL Priority
Mfg
Dec 1995 SUPPL
Mfg
Oct 1992 SUPPL
Mfg
Jan 1992 SUPPL
Mfg
Sep 1991 SUPPL Priority
Mfg
Oct 1989 SUPPL
Mfg
Mar 1989 SUPPL Priority
Mfg
May 1988 SUPPL
Label
May 1988 SUPPL Priority
Mfg
Dec 1987 SUPPL
Label
Oct 1987 ORIGINAL
Update
Oct 1987 SUPPL Priority
Mfg
Sep 1987 SUPPL
Label
Jul 1987 SUPPL Priority
Mfg
May 1987 SUPPL Priority
Mfg
Apr 1987 SUPPL
Label
Aug 1986 SUPPL
Label
Sep 1985 SUPPL Priority
Mfg
Jun 1985 SUPPL
Label
Jun 1985 SUPPL Priority
Mfg
May 1985 SUPPL Priority
Mfg
Jan 1985 SUPPL Priority
Mfg
Aug 1984 SUPPL
Label
Aug 1984 SUPPL
Efficacy
Aug 1984 SUPPL Priority
Mfg
Jul 1983 SUPPL Priority
Mfg
Mar 1983 SUPPL Priority
Mfg
Mar 1983 SUPPL Priority
Mfg
Dec 1981 ORIGINAL Priority
New Drug
What PIPRACIL Treats
3 FDA approvalsOriginally approved for its first indication in 1981 . Covers 3 distinct patient populations.
- Other (3)
Other
(3 approvals)- • Approved indication (Dec 1981) Priority
- • Approved indication (Aug 1984)
- • Approved indication (Oct 1987)
Pfizer's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
HYMPAVZI
2024 MARSTACIMAB-HNCQ
2 designations
ZAVZPRET
2023 ZAVEGEPANT HYDROCHLORIDE
NGENLA
2023 SOMATROGON-GHLA
1 designation
VELSIPITY
2023 ETRASIMOD ARGININE
PAXLOVID (COPACKAGED)
2023 NIRMATRELVIR
3 designations
LITFULO
2023 RITLECITINIB TOSYLATE
ELREXFIO
2023 ELRANATAMAB
5 designations
CIBINQO
2022 ABROCITINIB
2 designations
NURTEC ODT
2020 RIMEGEPANT SULFATE
VIZIMPRO
2018 DACOMITINIB
2 designations
DAURISMO
2018 GLASDEGIB MALEATE
2 designations
TALZENNA
2018 TALAZOPARIB TOSYLATE
1 designation
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PIPRACIL FDA Label Details
Track PIPRACIL with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.